[Clinical and hemodynamic effects of disopyramide phosphate administered i.v. in cardiopathic subjects (author's transl)].
The antiarrhythmic action of disopyramide (1.5 mg/Kg) administered i.v. as a bolus was assessed in 30 patients with ischemic heart disease and different arrhythmias. In 75% of supraventricular parossistic tachycardia and in 75% of parossistic atrial fibrillation, arrhythmia was interrupted within few minutes from drug injection; in 90% with premature ventricular contractions (PVC) and in 100% of ventricular tachycardia, disopyramide was capable to interrupt the arrhythmias. The hemodynamic effects of the same dose of disopyramide were evaluated in other 17 patients, 9 of which in I-II class NYHA and 8 in III-IV class. We used STI's as parameters of cardiac performance. In all patients following the injection of disopyramide, a significant increase of PEP, ICT and PEP/LVET ratio and a significant decrease of LVETc were observed. Thus, the disopyramide impaired cardiac performance and its effect appeared more evident in patients in III-IV class NYHA. In conclusion, disopyramide showed to be effective in interrupting different arrhythmias; however, its depressant action on cardiac performance suggests that caution should be used in patients with severely impaired myocardial function.
D000328:Adult; D001145:Arrhythmias, Cardiac / Q000188:drug therapy*; D003327:Coronary Disease / Q000188:drug therapy*; D004206:Disopyramide / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D004562:Electrocardiography; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000008:administration & dosage*; D013599:Systole / Q000187:drug effects
D011725:Pyridines; D004206:Disopyramide
Effeti clinici ed emodinamici della disopiramide fosfato per via venosa in pazienti cardiopatici.